Perry Franklin Renshaw
Hearing Aid Provider in Salt Lake City, UT
License number
Utah 6901476-8914
Issued Date
Oct 11, 2012
Expiration Date
Sep 30, 2015
Category
xControlled Substance Handler
Type
Controlled Substance Handler Individual
Address
Address
Salt Lake City, UT
Education
UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE
Personal information
See more information about Perry Franklin Renshaw at radaris.comName
Address
Phone
383 Colorow Dr, Salt Lake City, UT 84108
4358 E Laneview Ct, Salt Lake City, UT 84108
Professional information
Perry Franklin Renshaw, Salt Lake City UT
Specialties:
Psychiatrist
Address:
50 N Medical Dr, Salt Lake City, UT 84132
Education:
University of Pennsylvania, Perelman School of Medicine - Doctor of Medicine*
University of Pennsylvania - Doctor of Philosophy*
Massachusetts General Hospital - Residency - Psychiatry*
University of Pennsylvania - Doctor of Philosophy*
Massachusetts General Hospital - Residency - Psychiatry*
Board certifications:
American Board of Psychiatry and Neurology Certification in Psychiatry (Psychiatry and Neurology)*
Dr. Perry F Renshaw, Belmont MA - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Psychiatry)
Address:
Belmont Office
115 Mill St, Belmont 02478
(617) 855-2000 (Phone), (617) 855-3810 (Fax)
UNIVERSITY OF UTAH HOSPITAL
383 S Colorow Dr SUITE 309, Salt Lake City 84108
(801) 587-1216 (Phone)
115 Mill St, Belmont 02478
(617) 855-2000 (Phone), (617) 855-3810 (Fax)
UNIVERSITY OF UTAH HOSPITAL
383 S Colorow Dr SUITE 309, Salt Lake City 84108
(801) 587-1216 (Phone)
Certifications:
Psychiatry, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1988
Brigham and Womens Hospital
Massachusetts General Hospital
Perelman School of Medicine University of Pennsylvania
Graduated: 1988
Brigham and Womens Hospital
Massachusetts General Hospital
Perry Renshaw, Belmont MA
Work:
McLean Hospital
115 Mill St, Belmont, MA 02478 VA Salt Lake City Health Care System
500 Foothill Dr, Salt Lake City, UT 84148
115 Mill St, Belmont, MA 02478 VA Salt Lake City Health Care System
500 Foothill Dr, Salt Lake City, UT 84148
Pyrimidines, Such As Uridine, In Treatments For Patients With Bipolar Disorder
US Patent:
2010022, Sep 2, 2010
Filed:
May 12, 2010
Appl. No.:
12/778637
Inventors:
Perry Renshaw - Salt Lake City UT, US
Assignee:
The McLean Hospital Corporation - Belmont MA
International Classification:
A61K 31/7072, A61P 25/22, A61P 25/18
US Classification:
514 50
Abstract:
The invention is based on the discovery that specific dosages of pyrimidine compositions, such as uridine compositions, can be used to treat patients diagnosed with bipolar disorder.
Methods For The Treatment Of Psychiatric Disorders
US Patent:
2013028, Oct 24, 2013
Filed:
May 13, 2011
Appl. No.:
13/697674
Inventors:
Perry F. Renshaw - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
The McLean Hospital Corporation - Belmont MA
The McLean Hospital Corporation - Belmont MA
International Classification:
A61K 31/198, A61K 45/06
US Classification:
514120, 514565, 514392, 514275
Abstract:
The invention provides methods for the treatment of major depressive disorder in male subjects and methods for the treatment of psychiatric disorders at high altitudes by administering one or more creatine-containing compounds.
Pyrimidines, Such As Uridine, In Treatments For Patients With Bipolar Disorder
US Patent:
7737128, Jun 15, 2010
Filed:
Jun 10, 2005
Appl. No.:
11/629111
Inventors:
Perry Renshaw - Salt Lake City UT, US
Assignee:
The McLean Hospital Corporation - Belmont MA
International Classification:
A01N 43/04, A61K 31/70
US Classification:
514 50, 514 42, 514 43, 514 49
Abstract:
The invention is based on the discovery that specific dosages of pyrimidine compositions, such as uridine compositions, can be used to treat patients diagnosed with bipolar disorder.
Depression Disorder Therapeutics With Creatine Analogs
US Patent:
2013032, Dec 5, 2013
Filed:
Oct 7, 2011
Appl. No.:
13/878191
Inventors:
Perry F. Renshaw - Salt Lake City UT, US
Douglas G. Kondo - Salt Lake City UT, US
Douglas G. Kondo - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
International Classification:
A61K 31/195, A61K 45/06
US Classification:
514565
Abstract:
In one aspect, the invention relates to creatine analogs, compositions comprising same, and methods of using same, alone or in combination with other agents, to treat depression disorders and associated maladies. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Pyrimidines, Such As Cytidine, In Treatments For Patients With Biopolar Disorder
US Patent:
2009021, Aug 27, 2009
Filed:
Jun 10, 2005
Appl. No.:
11/629110
Inventors:
Perry Renshaw - Salt Lake City UT, US
Bruce Cohen - Lexington MA, US
Bruce Cohen - Lexington MA, US
International Classification:
A61P 25/24, A61K 31/7068
US Classification:
514 47, 514 46
Abstract:
The invention is based on the discovery that specific dosages of pyrimidine compositions, such as cytidine compositions, can be used to treat patients diagnosed with bipolar disorder.
Methods For Improving Frontal Brain Bioenergetic Metabolism
US Patent:
2010004, Feb 18, 2010
Filed:
Aug 14, 2009
Appl. No.:
12/541452
Inventors:
Perry Renshaw - Salt Lake City UT, US
International Classification:
A61K 31/7072, A61K 31/7068, A61P 25/00
US Classification:
514 50, 514 49
Abstract:
The invention provides methods and compositions for augmenting bioenergetic metabolism in the frontal brain involving administration of a cytidine-containing or uridine-containing compound to a human.
Methods And Compositions For Improving Cognitive Performance
US Patent:
2010004, Feb 18, 2010
Filed:
Aug 14, 2009
Appl. No.:
12/541504
Inventors:
Perry Renshaw - Salt Lake City UT, US
International Classification:
A61K 31/7068, A61K 31/7072
US Classification:
514 51, 514 49
Abstract:
The invention provides methods and compositions for improving cognitive performance involving administration of a cytidine-containing or uridine-containing compound to a neuropsychologically healthy human.